Advertisement

Roche Buys Biotech for $8.3B

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

By | August 27, 2014

FLICKR, SERGEI GOLYSHEVPirfenidone, a treatment for a fatal lung disease known as idiopathic pulmonary fibrosis (IPF), was approved for sale in Canada in 2011 and in Europe the following year. Big Pharma firm Roche has bought the drug’s developer, Brisbane, California-based InterMune, while it awaits approval for pirfenidone from the US Drug and Food Administration (FDA). InterMune cost Roche a cool $8.3 billion. Howard Liang, a stock analyst with Leerink Partners, said that sales of pirfenidone will likely reach $1.6 billion in 2020, Chemical & Engineering News reported.

“[Acquiring InterMune is] recognition of the potential to develop a fibrosis franchise with pirfenidone as a starting point,” Liang said. “[The Roche acquisition] represents a favorable ending of the InterMune story, which has endured an arduous road in pioneering the development of the first approved treatment for idiopathic pulmonary fibrosis.”

In 2010, the FDA denied approval of InterMune’s pirfenidone, which works by inhibiting synthesis of the cellular regulator TGF-β and of the cytokine TNF-α. Following another Phase 3 trial, the company refiled for approval this spring, and in July, the drug received the FDA’s breakthrough therapy designation. Last year, InterMune suffered a net loss of $220 million.

Roche’s buyout caps a series of acquisitions made by the company in the past year. This month, Roche paid $450 million for the RNA-drug company Santaris Pharma, and in July, the company paid $1.73 billion for the cancer drug firm Seragon Pharmaceuticals.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo
Advertisement

Popular Now

  1. Opinion: Too Many Mitochondrial Genome Papers
  2. Antibiotics and the Gut Microbiome
  3. Sex Differences in Pain Pathway
  4. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

Advertisement
Shimadzu Scientific
Shimadzu Scientific
Advertisement
The Scientist